牛牛AI助理已提取核心訊息
On December 31, 2023, Ariel Gordon filed an amendment to Schedule 13G/A with the United States Securities and Exchange Commission, disclosing a 6.9% ownership stake in NeuroSense Therapeutics Ltd., which includes warrants to purchase 25,954 ordinary shares. The filing indicates that Gordon now beneficially owns 1,060,561 shares in the biotechnology company, based on 15,379,042 ordinary shares outstanding as provided by NeuroSense Therapeutics. The address for NeuroSense Therapeutics' principal executive offices is listed as 11 Hamenofim Street, Herzliya, Israel. Ariel Gordon, who holds both Israeli and U.S. citizenship, has sole voting and dispositive power over the shares. The filing was completed on February 13, 2024, and asserts that the acquisition of the shares is not for the purpose of changing or influencing the control of the issuer, nor is it in connection with any transaction having that purpose or effect.
On December 31, 2023, Ariel Gordon filed an amendment to Schedule 13G/A with the United States Securities and Exchange Commission, disclosing a 6.9% ownership stake in NeuroSense Therapeutics Ltd., which includes warrants to purchase 25,954 ordinary shares. The filing indicates that Gordon now beneficially owns 1,060,561 shares in the biotechnology company, based on 15,379,042 ordinary shares outstanding as provided by NeuroSense Therapeutics. The address for NeuroSense Therapeutics' principal executive offices is listed as 11 Hamenofim Street, Herzliya, Israel. Ariel Gordon, who holds both Israeli and U.S. citizenship, has sole voting and dispositive power over the shares. The filing was completed on February 13, 2024, and asserts that the acquisition of the shares is not for the purpose of changing or influencing the control of the issuer, nor is it in connection with any transaction having that purpose or effect.
2023年12月31日，愛麗兒·戈登向美國證券交易委員會提交了附表13G/A的修正案，披露了NeuroSense Therapeutics Ltd. 6.9％的所有權，其中包括購買25,954股普通股的認股權證。該文件顯示，根據NeuroSense Therapeutics提供的15,379,042股已發行普通股，戈登現在實益擁有這家生物技術公司的1,060,561股股份。NeuroSense Therapeutics主要行政辦公室的地址列爲以色列赫茲利亞哈梅諾菲姆街11號。擁有以色列和美國國籍的愛麗爾·戈登對股票擁有唯一的投票權和處置權。該文件於2024年2月13日完成，並斷言收購這些股份的目的不是爲了改變或影響發行人的控制權，也與任何具有該目的或效力的交易有關。
2023年12月31日，愛麗兒·戈登向美國證券交易委員會提交了附表13G/A的修正案，披露了NeuroSense Therapeutics Ltd. 6.9％的所有權，其中包括購買25,954股普通股的認股權證。該文件顯示，根據NeuroSense Therapeutics提供的15,379,042股已發行普通股，戈登現在實益擁有這家生物技術公司的1,060,561股股份。NeuroSense Therapeutics主要行政辦公室的地址列爲以色列赫茲利亞哈梅諾菲姆街11號。擁有以色列和美國國籍的愛麗爾·戈登對股票擁有唯一的投票權和處置權。該文件於2024年2月13日完成，並斷言收購這些股份的目的不是爲了改變或影響發行人的控制權，也與任何具有該目的或效力的交易有關。
有用
沒用
